Lialin Tony Serge
Known title: Chief Commercial OfficerCIK: 0002082194
Lialin Tony Serge's purchase track record
Lialin Tony Serge has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2026 | VIVS | $3K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VIVS | ▲ Buy | Open Market | 10,000 | $3K | 8/31/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing
Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.
Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing. Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.